Valneva SE (VALN) Stock Analysis & Winston Score

Valneva SE is a French biotechnology company that makes vaccines for infectious diseases. Its most important product is IXCHIQ, a vaccine for chikungunya — a painful viral illness spread by mosquitoes — which became the first approved chikungunya vaccine in the world when the U.S. FDA cleared it in late 2023. The company also sells IXIARO, a travel vaccine for Japanese encephalitis, primarily to military and travel medicine customers. Valneva earns money by selling its approved vaccines to governments, militaries, and travel health clinics, mainly in the United States and Europe. It is a small company with a market cap around $500 million, and its main competitive edge is being the only maker of an approved chikungunya vaccine. However, the company is currently losing money — its operating margin is deeply negative — and the key risk is whether IXCHIQ can achieve broad commercial adoption fast enough to offset ongoing research and operating costs.